Document Detail

Spironolactone management of resistant hypertension.
MedLine Citation:
PMID:  20978214     Owner:  NLM     Status:  In-Process    
OBJECTIVE: To review the pharmacology, pharmacokinetics, pharmacodynamics, efficacy data, and adverse effects of spironolactone in the treatment of resistant hypertension.
DATA SOURCES: A literature search was conducted using MEDLINE (1966-July 2010), International Pharmaceutical Abstracts (1970-July 2010), and Cochrane database (2009) for the key words spironolactone or resistant hypertension. References cited in the articles were reviewed for additional information.
STUDY SELECTION AND DATA EXTRACTION: English-language literature reporting pharmacology data from animal studies and clinical trials evaluating the pharmacology, pharmacokinetics, pharmacodynamics, efficacy data, and adverse effects of spironolactone were included.
DATA SYNTHESIS: Spironolactone is a potassium-sparing diuretic with anti-aldosterone effects that are beneficial in the management of hypertension. Spironolactone has shown improvement in 5 prospective studies and 1 retrospective study evaluating its blood pressuring-lowering abilities in patients with resistant hypertension. Specifically, the average blood pressure lowering noted in these trials with the addition of spironolactone in patients with resistant hypertension was 22/10 mm Hg. Trials evaluating spironolactone's role in resistant hypertension treatment have identified hyperkalemia, gynecomastia, and renal insufficiency as the major adverse effects that warrant monitoring.
CONCLUSIONS: Spironolactone is an appropriate antihypertensive medication to add to treatment of patients with resistant hypertension (≥3 antihypertensive medications at optimal doses) not at their blood pressure goal. In patients considered to have resistant hypertension, secondary causes should be ruled out.
Joel C Marrs
Related Documents :
20429314 - Diastolic blood pressure as a major determinant of tissue perfusion: potential clinical...
21054774 - Rationale for triple-combination therapy for management of high blood pressure.
12140724 - Combination therapy with at(1)-receptor blockers.
22805284 - Oxygenation and plasma endothelin-1 concentrations in healthy horses recovering from is...
12114964 - Effect of high hydrostatic pressure on activity of restriction endonucleases.
9255654 - Drawover vaporizers for sedation in intensive care.
Publication Detail:
Type:  Journal Article     Date:  2010-10-26
Journal Detail:
Title:  The Annals of pharmacotherapy     Volume:  44     ISSN:  1542-6270     ISO Abbreviation:  Ann Pharmacother     Publication Date:  2010 Nov 
Date Detail:
Created Date:  2010-11-04     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9203131     Medline TA:  Ann Pharmacother     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1762-9     Citation Subset:  IM    
Department of Clinical Pharmacy, University of Colorado, Aurora, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Sepsis bundles: just do it.
Next Document:  Assessing the effect of the surviving sepsis campaign treatment guidelines on clinical outcomes in a...